Does Chronic Use of High Dose Proton Pump Inhibitors Increase Risk for Pancreatic Cancer?

ABSTRACT:

Objectives

To analyze whether use of proton pump inhibitors increase the risk for pancreatic cancer in a mouse model and human clinical cohorts.

Methods

p48-Cre/LSL-KrasG12D mice that develop precancerous pancreatic intraepithelial neoplasia (PanINs) were treated with low- or high-dose proton pump inhibitors (PPIs) orally for 1 and 4 months. The mechanism for the cholecystokinin receptor 2 (CCK-2R) activation was investigated in vitro. Two resources were employed to analyze the risk of pancreatic cancer in human subjects with PPI use.

Results

Serum gastrin levels were increased 8-fold (P < 0.0001) in mice treated with chronic high-dose PPIs, and this change correlated with an increase (P = 0.02) in PanIN grade and the development of microinvasive cancer. The CCK-2R ex

SUBMITTER: Huber MA 

PROVIDER: S-EPMC10119745 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature